PIM kinase inhibition:co-targeted therapeutic approaches in prostate cancer
作者机构：Molecular Diagnostics and Therapeutics GroupUniversity College LondonLondonUK Trinity Translational Medicine InstituteSt.James’s Hospital DublinDublin 8DublinIreland
出 版 物：《Signal Transduction and Targeted Therapy》 (信号转导与靶向治疗（英文）)
年 卷 期：2020年第5卷第1期
页 面：2430-2439页
核心收录：
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：Prostate Cancer UK for funding SH under a Travelling Prize Fellowship the support of the Prostate Cancer UK Centre of Excellence
摘 要：PIM kinases have been shown to play a role in prostate cancer development and progression,as well as in some of the hallmarks of cancer,especially proliferation and *** upregulation in prostate cancer has been correlated with decreased patient overall survival and therapy *** efforts to inhibit PIM with monotherapies have been hampered by compensatory upregulation of other pathways and drug toxicity,and as such,it has been suggested that co-targeting PIM with other treatment approaches may permit lower doses and be a more viable option in the ***,we present the rationale and basis for cotargeting PIM with inhibitors of PI3K/mTOR/AKT,JAK/STAT,MYC,stemness,and RNA Polymerase I transcription,along with other therapies,including androgen deprivation,radiotherapy,chemotherapy,and *** combined approaches could potentially be used as neoadjuvant therapies,limiting the development of resistance to treatments or sensitizing cells to other *** determine which drugs should be combined with PIM inhibitors for each patient,it will be key to develop companion diagnostics that predict response to each co-targeted option,hopefully providing a personalized medicine pathway for subsets of prostate cancer patients in the future.
维普期刊数据库